PME-1 suppresses anoikis, and is associated with therapy relapse of PTEN-deficient prostate cancers
Aakula, A.; Isomursu, A.; Rupp, C.; Erickson, A.; Kauko, O.; Shah, P.; Padzik, A.; Pokharel, Y. R.; Kaur, A.; Li, S.-P.; Trottman, L.; Taimen, P.; Rannikko, A.; Lammerding, J.; Paatero, I.; Mirtti, T.; Ivaska, J.; Westermarck, J.
Show abstract
While organ-confined PCa is mostly therapeutically manageable, metastatic progression of PCa remains an unmet clinical challenge. Resistance to anoikis, a form of cell death initiated by cell detachment from the surrounding extracellular matrix, is one of the cellular processes critical for PCa progression towards aggressive disease. Therefore, further understanding of anoikis regulation in PCa might provide therapeutic opportunities. Here, we discover that PCa tumors with concomitantly compromised function of two tumor suppressor phosphatases, PP2A and PTEN, are particularly aggressive, having less than 50% 5-year secondary-therapy free patient survival. Functionally, overexpression of PME-1, a PP2A inhibitor protein, inhibits anoikis in PTEN-deficient PCa cells. In vivo, PME-1 inhibition increased apoptosis in in ovo PCa tumor xenografts, and attenuated PCa cell survival in zebrafish circulation. Molecularly, PME-1 deficient PCa cells display increased trimethylation at lysines 9 and 27 of histone H3 (H3K9me3 and H3K27me3), a phenotype corresponding to increased apoptosis sensitivity. In summary, we discover that PME-1 overexpression supports anoikis resistance in PTEN-deficient PCa cells. Clinically, the results identify PME-1 as a candidate biomarker for a subset of particularly aggressive PTEN-deficient PCa.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.